HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition
Class I histone deacetylases (HDACs) generally promote cell proliferation and tumorigenesis, whereas class IIA HDACs like HDAC4 and HDAC5 may promote or impede cancer development in a tissue-dependent manner. In urothelial carcinoma (UC), HDAC5 is often downregulated. Accordingly, HDAC5 was weakly e...
Main Authors: | Ananda Ayyappan Jaguva Vasudevan, Michèle J. Hoffmann, Michael L. C. Beck, Gereon Poschmann, Patrick Petzsch, Constanze Wiek, Kai Stühler, Karl Köhrer, Wolfgang A. Schulz, Günter Niegisch |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/9/2135 |
Similar Items
-
Effects of novel HDAC inhibitors on urothelial carcinoma cells
by: Aline Kaletsch, et al.
Published: (2018-07-01) -
Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
by: Elizabeth A. Thomas
Published: (2014-05-01) -
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
by: Maria Cosenza, et al.
Published: (2018-08-01) -
Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
by: Giorgio Milazzo, et al.
Published: (2020-05-01) -
HDAC3 and HDAC8 are required for cilia assembly and elongation
by: Seon-ah Park, et al.
Published: (2019-08-01)